Literature DB >> 21340598

[Use of marker systems in the treatment of bladder cancer].

M Burger1, F Vom Dorp.   

Abstract

Accepted prognostic factors for urothelial carcinomas of the bladder are tumor grade, T category, and in cases of muscle invasive carcinoma lymph node status. These morphological criteria correlate in general with the clinical course of patients suffering from bladder cancer. Beside histomorphological criteria the search for prognostic markers independent of histological evaluation seems to be important as the clinical course of bladder cancer patients can be very heterogeneous. For this purpose we reviewed the current literature and focussed on additional molecular markers with prognostic relevance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21340598     DOI: 10.1007/s00120-010-2412-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  45 in total

1.  Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder.

Authors:  Marco G Bol; Jan P Baak; Susanne Buhr-Wildhagen; Arnold-Jan Kruse; Kjell H Kjellevold; Emiel A Janssen; Oddvar Mestad; Per Øgreid
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

2.  Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.

Authors:  E M Messing
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

3.  Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

Authors:  Jose A Karam; Yair Lotan; Pierre I Karakiewicz; Raheela Ashfaq; Arthur I Sagalowsky; Claus G Roehrborn; Shahrokh F Shariat
Journal:  Lancet Oncol       Date:  2007-02       Impact factor: 41.316

4.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

Authors:  J P Crew; T O'Brien; M Bradburn; S Fuggle; R Bicknell; D Cranston; A L Harris
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

5.  Expression of bcl-2 and bcl-X in bladder cancer.

Authors:  E J Kirsh; D A Baunoch; W M Stadler
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

6.  Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.

Authors:  Shahrokh F Shariat; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Journal:  Urol Oncol       Date:  2007 Nov-Dec       Impact factor: 3.498

7.  Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.

Authors:  Olga Modlich; Hans-Bernd Prisack; Gerald Pitschke; Uwe Ramp; Rolf Ackermann; Hans Bojar; Thomas A Vögeli; Marc-Oliver Grimm
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

8.  FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.

Authors:  D C Tomlinson; O Baldo; P Harnden; M A Knowles
Journal:  J Pathol       Date:  2007-09       Impact factor: 7.996

9.  Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade.

Authors:  M Burger; S Denzinger; A Hartmann; W-F Wieland; R Stoehr; E C Obermann
Journal:  Br J Cancer       Date:  2007-05-15       Impact factor: 7.640

10.  Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.

Authors:  A W Hitchings; M Kumar; S Jordan; V Nargund; J Martin; D M Berney
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

View more
  1 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.